Bristol-Myers Squibb Company is a global biopharmaceutical ... The company markets its products to a variety of clients, including hospitals, pharmacies, and government agencies, aiming to improve ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

One of the biggest risks for Bristol-Myers Squibb is the loss of patent (and probably resulting decline in sales) for its blockbuster products. And as I have pointed out in my last article ...

Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for Human Use of the European Medicines Agency for its drug repotrectinib in ...

Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...

Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Bristol Myers Squibb has been named a Top Socially Responsible ... considerations like the environmental impact of the company's products and services, as well as the company's efficiency in ...